197 related articles for article (PubMed ID: 23371261)
1. [Breast cancer. Individualized therapy concepts].
Harbeck N; Wuerstlein R
Internist (Berl); 2013 Feb; 54(2):194-9. PubMed ID: 23371261
[TBL] [Abstract][Full Text] [Related]
2. [Personalized therapy concepts for malignant melanoma].
Schlaak M; Kreuzberg N; Mauch C; Kurschat P
Internist (Berl); 2013 Feb; 54(2):188-93. PubMed ID: 23371260
[TBL] [Abstract][Full Text] [Related]
3. [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases].
Eschenhagen T; Blankenberg S
Internist (Berl); 2013 Feb; 54(2):147-8, 150-2, 154. PubMed ID: 23371262
[TBL] [Abstract][Full Text] [Related]
4. [Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
Schlenk RF; Döhner K; Döhner H
Internist (Berl); 2013 Feb; 54(2):171-8. PubMed ID: 23358744
[TBL] [Abstract][Full Text] [Related]
5. [Lung cancer. Molecular pathology and personalized therapy].
Schultheis A; Wolf J; Büttner R
Internist (Berl); 2013 Feb; 54(2):179-80, 182-7. PubMed ID: 23371257
[TBL] [Abstract][Full Text] [Related]
6. [Chronic lymphocytic leukemia. Treatment and genetic risk profile].
Stilgenbauer S; Hallek M
Internist (Berl); 2013 Feb; 54(2):164, 166-70. PubMed ID: 23371259
[TBL] [Abstract][Full Text] [Related]
7. Validated biomarkers: The key to precision treatment in patients with breast cancer.
Duffy MJ; O'Donovan N; McDermott E; Crown J
Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
[TBL] [Abstract][Full Text] [Related]
8. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
9. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
11. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
12. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
13. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
14. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
[TBL] [Abstract][Full Text] [Related]
15. Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
Murciano-Goroff YR; McCarthy AM; Bristol MN; Groeneveld P; Domchek SM; Motanya UN; Armstrong K
Breast Cancer Res Treat; 2018 Aug; 171(1):173-180. PubMed ID: 29737473
[TBL] [Abstract][Full Text] [Related]
16. [Tailored management of chronic myeloid leukemia].
Hochhaus A; La Rosée P
Internist (Berl); 2013 Feb; 54(2):155-6, 158-60, 162-3. PubMed ID: 23371258
[TBL] [Abstract][Full Text] [Related]
17. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
[TBL] [Abstract][Full Text] [Related]
18. [BREAST CANCER: FROM TARGETED THERAPY TO PRECISION MEDICINE].
Jerusalem G; Collignon J; Josse C; Schroeder H; Rorive A; Frères P; Lambert F; Koopmansch B; Poncin A; Bours V
Rev Med Liege; 2015; 70(5-6):269-76. PubMed ID: 26285451
[TBL] [Abstract][Full Text] [Related]
19. [Personalized tumor therapy for gastrointestinal tumors].
Ettrich TJ; Perkhofer L; Seufferlein T
Internist (Berl); 2015 Sep; 56(9):1069-78. PubMed ID: 26148698
[TBL] [Abstract][Full Text] [Related]
20. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]